Wedbush raised the firm’s price target on Day One Biopharmaceuticals (DAWN) to $30 from $29 and keeps an Outperform rating on the shares following quarterly results. The firm looks forward to commercial growth, as well as continued development of Ojemda in front line pLGG in 2026; FIREFLY-2 remains on track to be fully enrolled, with eventual data readout and potential approval likely in 2027 and 2028, respectively.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DAWN:
- Day One Biopharmaceuticals: Durable OJEMDA Launch, De‑Risked Revenue Outlook, and Clinical Catalysts Underpin Buy Rating and $17 Price Target
- Day One price target lowered to $22 from $25 at H.C. Wainwright
- Buy Rating Backed by Strong Ojemda Outperformance, Reaffirmed 2026 Revenue Outlook, and Pipeline Clinical Catalysts
- Day One Highlights Transformational 2025 and OJEMDA Growth
- Day One Biopharmaceuticals reports Q4 revenue $52.8M, consensus $49.81M